Remove Dermatitis Remove Pharmaceutical Remove Therapy
article thumbnail

Case 2: Female, 15 Years Old

Dermatology Times

Dr Bhutani presents the case of a 15-year-old female with long standing atopic dermatitis and discusses the importance of balancing parental preferences for "natural" agents with effective pharmaceutical options.

article thumbnail

LEVEL UP Period 2 Data: AD Patients Who Switched From Dupilumab to Upadacitinib Hit Higher Treatment Targets

The Dermatology Digest

Atopic dermatitis (AD) patients who switched to upadacitinib (Rinvoq, AbbVie) from dupilumab (Dupixent, Regeneron, and Sanofi) hit higher treatment targets, according to results from Period 2 of the LEVEL UP study. The most frequently reported TEAEs included nasopharyngitis, acne, upper respiratory tract infection, and atopic dermatitis.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Oh, The Places Dermatology Will Go in 2024!

The Dermatology Digest

This will be a game-changer if it pans out and may get us closer to disease cures via optimization of existing biological therapies,” he says. Dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc., Hands Up for New CHE therapies Chronic hand eczema (CHE) will also get some love in 2024. And the Skin Disease of the Year Is….

article thumbnail

Breaking News: Japan First in the World to Approve Dupilumab for CSU

The Dermatology Digest

The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.) for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy.

article thumbnail

There’s Something About Eblasakimab: Aslan, Zenyaku Partner to Investigate How it Differs From Other Biologics for AD

The Dermatology Digest

Aslan and Zenyaku are teaming up to explore how eblasakimab’s mechanism of action differs from that of other biologic therapies for atopic dermatitis (AD).

article thumbnail

Off-label Pearl: Exploring the Role of Narrowband UVB Phototherapy Plus Oral JAK Inhibitors in Vitiligo

The Dermatology Digest

Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Topical isotretinoin, even when covering 90% of a patient’s body surface area, showed minimal systemic absorption. Watch Now The Lowdown on Molluscum Nanette B. Watch Now Biosimilars in Dermatology: Where Do They Fit in?

article thumbnail

Sneak Peek Inside the CSU Treatment Pipeline

The Dermatology Digest

Silverberg, MD Molluscum Contagiosum appears to be on the rise and often travels with atopic dermatitis (AD). Topical isotretinoin, even when covering 90% of a patient’s body surface area, showed minimal systemic absorption. Watch Now The Lowdown on Molluscum Nanette B. Watch Now Biosimilars in Dermatology: Where Do They Fit in?